Display options
Cite
Bhowmik M, Majumdar S, Dasgupta A, et al. Pilot-Scale Study Of Human Plasma Proteomics Identifies ApoE And IL33 As Markers In Atopic Asthma. J Asthma Allergy. 2019;12:273-283doi: 10.2147/JAA.S211569.
Bhowmik, M., Majumdar, S., Dasgupta, A., Gupta Bhattacharya, S., & Saha, S. (2019). Pilot-Scale Study Of Human Plasma Proteomics Identifies ApoE And IL33 As Markers In Atopic Asthma. Journal of asthma and allergy, 12273-283. https://doi.org/10.2147/JAA.S211569
Bhowmik, Moumita, et al. "Pilot-Scale Study Of Human Plasma Proteomics Identifies ApoE And IL33 As Markers In Atopic Asthma." Journal of asthma and allergy vol. 12 (2019): 273-283. doi: https://doi.org/10.2147/JAA.S211569
Bhowmik M, Majumdar S, Dasgupta A, Gupta Bhattacharya S, Saha S. Pilot-Scale Study Of Human Plasma Proteomics Identifies ApoE And IL33 As Markers In Atopic Asthma. J Asthma Allergy. 2019 Sep 20;12:273-283. doi: 10.2147/JAA.S211569. eCollection 2019. PMID: 31571934; PMCID: PMC6759800.
Copy Download .nbib Format: NLM
Share it on

J Asthma Allergy. 2019 Sep 20;12:273-283. doi: 10.2147/JAA.S211569. eCollection 2019.

Pilot-Scale Study Of Human Plasma Proteomics Identifies ApoE And IL33 As Markers In Atopic Asthma.

Journal of asthma and allergy

Moumita Bhowmik, Sreyashi Majumdar, Angira Dasgupta, Swati Gupta Bhattacharya, Sudipto Saha

Affiliations

  1. Division of Plant Biology, Bose Institute, Kolkata, West Bengal, India.
  2. Division of Bioinformatics, Bose Institute, Kolkata, West Bengal, India.
  3. BR Singh Hospital and Centre for Medical Education and Research, Kolkata, West Bengal, India.

PMID: 31571934 PMCID: PMC6759800 DOI: 10.2147/JAA.S211569

Abstract

BACKGROUND: The pathobiology of atopic asthma is complex and the symptoms similar to other respiratory diseases. As such, identification of biomarkers of atopic asthma is of prime importance for better diagnosis and control of the disease.

OBJECTIVES: We sought to study the changes in plasma proteome and cytokine-expression profile across healthy and atopic asthmatics for identifying biomarkers and exploring aberrant pathways for atopic asthma.

METHODS: A pilot-scale study in humans was performed to identify differentially expressed proteins in blood plasma of healthy controls (n=5) and treatment-naïve atopic asthma patients (n=5) using quantitative label-free liquid chromatography-tandem mass spectrometry proteomics and ELISA.

RESULTS: Mass spectrometry-based proteomic analysis revealed ApoE to be significantly downregulated in atopic asthmatics compared to healthy volunteers. Decreased expression of ApoE in atopic asthmatics was validated by immunoblotting (50.74% decrease). Comparison with atopic asthmatics and COPD patients showed that ApoE was decreased (36.33%) in atopic asthma compared to COPD. IL33 was significantly upregulated in atopic asthmatics compared to healthy subjects (3.84-fold).

CONCLUSION: ApoE was downregulated and IL33 upregulated in atopic asthma patients compared to healthy volunteers. These two proteins' profiles were distinct in atopic asthma from healthy and COPD plasma samples. Differential expression of these proteins could serve as a probable candidate for a two-protein classifier-based prognostic biomarker of atopic asthma.

© 2019 Bhowmik et al.

Keywords: ApoE; IL33; LC-MS/MS; apolipoprotein E; atopic asthma; biomarkers; interleukin 33

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

  1. J Clin Invest. 2016 Jul 1;126(7):2394-403 - PubMed
  2. Front Genet. 2014 Jan 08;4:308 - PubMed
  3. Respir Med. 1999 Dec;93(12):903-8 - PubMed
  4. J Immunol. 2010 Jul 15;185(2):1222-9 - PubMed
  5. Science. 2015 Jan 23;347(6220):1260419 - PubMed
  6. Am J Physiol Lung Cell Mol Physiol. 2015 Jan 15;308(2):L130-40 - PubMed
  7. Curr Opin Pulm Med. 2009 Jan;15(1):12-8 - PubMed
  8. BMC Med Genomics. 2008 Apr 25;1:12 - PubMed
  9. Ann Am Thorac Soc. 2017 Nov;14(Supplement_5):S399-S405 - PubMed
  10. Am J Respir Crit Care Med. 2010 Nov 15;182(10):1228-38 - PubMed
  11. Am J Physiol Lung Cell Mol Physiol. 2015 Apr 1;308(7):L619-27 - PubMed
  12. Int J Chron Obstruct Pulmon Dis. 2017 Jan 21;12:395-402 - PubMed
  13. Int J Immunopathol Pharmacol. 2016 Jun;29(2):195-204 - PubMed
  14. Mol Biosyst. 2007 May;3(5):354-60 - PubMed
  15. Nat Rev Immunol. 2010 Feb;10(2):103-10 - PubMed
  16. Clin Pharmacol Drug Dev. 2016 Mar;5(2):102-8 - PubMed
  17. NeuroRx. 2004 Apr;1(2):182-8 - PubMed
  18. Carcinogenesis. 2000 Mar;21(3):517-24 - PubMed
  19. Pulm Pharmacol Ther. 2013 Aug;26(4):430-7 - PubMed
  20. Clin Exp Allergy. 2017 Nov;47(11):1426-1435 - PubMed
  21. Eur Respir J. 2005 Aug;26(2):319-38 - PubMed
  22. J Allergy Clin Immunol. 2014 Feb;133(2):388-94 - PubMed
  23. J Asthma. 2014 Dec;51(10):1004-13 - PubMed
  24. Int Arch Allergy Immunol. 2016;169(1):51-6 - PubMed
  25. Respir Res. 2016 Jan 14;17:5 - PubMed
  26. J Immunol. 2018 Apr 1;200(7):2253-2262 - PubMed
  27. Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3414-9 - PubMed
  28. Dtsch Arztebl Int. 2014 Dec 12;111(50):847-55 - PubMed
  29. ISRN Allergy. 2011 Dec 29;2011:195846 - PubMed
  30. Nat Rev Immunol. 2016 Nov;16(11):676-689 - PubMed
  31. Nat Protoc. 2006;1(6):2856-60 - PubMed
  32. Int J Gen Med. 2011;4:729-39 - PubMed
  33. Proteomics. 2009 Jan;9(2):470-84 - PubMed
  34. Int J Prev Med. 2017 Aug 31;8:65 - PubMed
  35. Clin Exp Allergy. 2015 Jul;45(7):1259-61 - PubMed
  36. Lipids Health Dis. 2016 Mar 22;15:59 - PubMed
  37. J Pharmacol Sci. 2014;126(2):85-91 - PubMed
  38. Respir Res. 2018 Jun 1;19(1):108 - PubMed
  39. J Asthma. 2009 Feb;46(1):91-4 - PubMed
  40. Mediators Inflamm. 2006;2006(5):65237 - PubMed
  41. Data Brief. 2016 Jul 26;8:1243-6 - PubMed
  42. J Biol Chem. 2005 Feb 18;280(7):5406-13 - PubMed
  43. Front Pharmacol. 2016 Sep 21;7:323 - PubMed
  44. J Asthma. 2006 Jan-Feb;43(1):75-80 - PubMed
  45. Am J Respir Crit Care Med. 2015 Sep 15;192(6):660-8 - PubMed

Publication Types